Sage Therapeutics (SAGE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SAGE Sage Therapeutics

Watchlist

6.080
-0.360-5.59%

Close Oct 31 16:00 ET

6.080
0.0000.00%

Post 20:01 ET

371.93MMarket Cap-1091P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $10 to $26
Moomoo NewsOct 31 09:00 ET · Ratings
Sage Therapeutics Price Target Lowered to $26 From $52 at Piper Sandler
Yahoo FinanceOct 31 07:39 ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
BenzingaOct 30 12:31 ET
Sage Therapeutics Price Target Cut to $8.00/Share From $9.00 by Oppenheimer
Dow JonesOct 30 12:13 ET · Ratings
Sage Therapeutics Is Maintained at Perform by Oppenheimer
Dow JonesOct 30 12:13 ET · Ratings
Sage Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results. Additionally, HC Wainwright & Co. Cut Its Price Target on the Stock From $25 to $14.
BenzingaOct 30 11:21 ET

Comments

Jaguar8

Oct 17 06:42

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...

Jaguar8

Oct 8 05:31

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...

Sikander KHAN

Jul 29 08:26

Don't expect exceptional Q2 results.

$Sage Therapeutics (SAGE.US)$ Stock is good, but sentiment is negative. I don't see any significant and sustainable upside by Q3. Another 20% to 30% downside is 'Likely'
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...

Trytosaveabit

Jul 24 05:39

Update

$Sage Therapeutics (SAGE.US)$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint